Expert Interview
A second in depth discussion of the clinical landscape for Macular Edema, with a close look at the phase 3 results of Kodiak Sciences tarcocimab and its potential in this space.
Ticker(s): KOD, REGNInstitution: Elman Retina Group
- Ophthalmologist in private practice; completed medical degree at the Baylor College of Medicine; finished two-year retina fellowship at The University of Chicago
- Specializes in surgical and medical care of retinal and vitreous diseases, such as macular degeneration, diabetic retinopathy and edema, and retinal detachments; sees 200-300 patients a week
- Authored multiple research articles in leading ophthalmology journals, as well as retinal textbook chapters
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
